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Abstract  1 
Objective: Depressive symptoms are an important risk factor and consequence of binge eating 2 
and purging behavior in bulimia nervosa (BN). Although psychotherapy is effective in reducing 3 
symptoms of BN in the short- and long-term, it is unclear whether psychotherapy for BN is also 4 
effective in reducing depressive symptoms. This meta-analysis examined the efficacy of 5 
psychotherapy for BN on depressive symptoms in the short and long-term. Method: 6 
Randomized controlled trials (RCTs) on BN that assessed depressive symptoms as an outcome 7 
were identified. Twenty-six RCTs were included. Results: Psychotherapy was more efficacious 8 
at reducing symptoms of depression at post-treatment (g=0.47) than wait-lists. This effect was 9 
strongest when studies delivered therapist-led, rather than guided self-help, treatment. No 10 
significant differences were observed between psychotherapy and antidepressants. There was no 11 
significant post-treatment difference between CBT and other active psychological comparisons 12 
at reducing symptoms of depression. However, when only therapist-led CBT was analyzed, 13 
therapist-led CBT was significantly more efficacious (g=0.25) than active comparisons at 14 
reducing depressive symptoms. The magnitude of the improvement in depressive symptoms was 15 
predicted by the magnitude of the improvement in BN symptoms. Discussion: These findings 16 
suggest that psychotherapy is effective for reducing depressive symptoms in BN in the short-17 
term. Whether these effects are sustained in the long-term is yet to be determined, as too few 18 
studies conducted follow-up assessments. Moreover, findings demonstrate that, in addition to 19 
being the front-running treatment for BN symptoms, CBT might also be the most effective 20 
psychotherapy for improving the symptoms of depression that commonly co-occur in BN.  21 
 Keywords: bulimia nervosa; cognitive-behavioural therapy; psychotherapy; depression; 22 
meta-analysis  23 
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Bulimia nervosa (BN) is a psychiatric disorder characterized by an over-evaluation of 1 
weight and shape and recurrent episodes of binge eating in combination with compensatory 2 
behavior (American Psychiatric Association, 2013). BN often runs a chronic course and is 3 
associated with serious medical complications, psychiatric comorbidity, and psychological 4 
impairment (Fairburn & Harrison, 2003). Randomized controlled trials (RCTs) have shown a 5 
range of psychological treatments, including cognitive-behavioral therapy (CBT), interpersonal 6 
psychotherapy (IPT) and dialectical behavior therapy (DBT), to be effective in reducing 7 
symptoms of BN in both the short and long-term (e.g., Agras, Walsh, Fairburn, Wilson, & 8 
Kraemer, 2000; Fairburn et al., 1991; Goldbloom et al., 1997; Poulsen et al., 2014; Safer, Telch, 9 
& Agras, 2001). Multiple systematic reviews of RCTs conclude that specific forms of CBT are 10 
the most effective treatment for BN (Hay, 2013; Hay, Bacaltchuk, Stefano, & Kashyap, 2009; 11 
Shapiro et al., 2007). This has prompted clinical guidelines to recommend CBT as the first line 12 
treatment for BN (Hay et al., 2014; National Institute of Clinical Excellence, 2017).  13 
Many individuals with BN also suffer from depression, either meeting criteria for a 14 
comorbid depressive disorder or reporting elevated symptoms of depression. For instance, recent 15 
research has shown that 60% of individuals with BN met criteria for a lifetime major depressive 16 
disorder (Godart et al., 2015), and early research that compared individuals with BN to 17 
individuals with major affective disorder reported comparable levels of depressive symptoms 18 
across both conditions (Cooper & Fairburn, 1986). Depressive symptoms are also said to be a 19 
major risk factor, maintaining factor, and consequence of BN (Fairburn & Harrison, 2003; 20 
Puccio, Fuller‐Tyszkiewicz, Ong, & Krug, 2016; Stice, 2001), and the two disorders share 21 
genetic risk factors (Slane, Burt, & Klump, 2011). Indeed, depressive symptoms have been 22 
shown to predict short and long-term BN persistence, poor treatment outcome, and relapse (Fahy 23 
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& Russell, 1993; Keski‐Rahkonen et al., 2013; Puccio et al., 2016; Vall & Wade, 2015), which 1 
suggests that depressive symptoms in BN should be an important target for treatment.  2 
Depressive symptoms are often included as a secondary treatment outcome in RCTs 3 
evaluating BN treatment. Numerous RCTs of psychological treatments for BN have reported 4 
large improvements in depressive symptoms from pre-treatment to post-treatment and follow-up 5 
(e.g., Cooper & Steere, 1995; Fairburn et al., 1991; Poulsen et al., 2014; Safer et al., 2001; 6 
Wonderlich et al., 2014). There is also evidence that CBT is more effective than alternative 7 
psychotherapy approaches (e.g., psychodynamic therapy, short-term focal psychotherapy, and 8 
supportive suppressive therapy) at reducing symptoms of depression in BN (Fairburn, Kirk, 9 
O'Connor, & Cooper, 1986; Garner et al., 1993; Poulsen et al., 2014).   10 
To date, one early meta-analysis has examined the effects of CBT for BN on symptoms 11 
of depression (Hay et al., 2009). The authors concluded that CBT significantly outperformed 12 
wait-list controls (k=7, d = 0.69, 95% CI = -1.09, -0.30) but not active psychological 13 
comparisons (k=13, d= -0.28, 95% CI = -0.57, 0.00) in reducing depressive symptoms at post-14 
treatment in individuals with BN and binge eating disorder (Hay et al., 2009). However, key 15 
questions still remain. First, evidence suggests that treatment non-response tends to be higher in 16 
BN than in BED samples (Castellini et al., 2011), suggesting we need to know if the beneficial 17 
effects of CBT or psychotherapy on depressive symptoms apply to individuals with BN 18 
specifically. Second, it is unknown whether these improvements are CBT-specific or whether 19 
other distinct psychotherapy approaches also show similar improvements in depressive 20 
symptoms. Third, moderators of the effects of CBT for BN on depressive symptoms have not 21 
been tested. For instance, it is not known whether different psychotherapy modalities that vary in 22 
duration have similar effects on depressive symptoms (i.e., a dose-response relationship), or 23 
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whether the improvements in depressive symptoms following psychotherapy are simply a 1 
consequence of BN symptom improvement. The latter question is crucial for understanding the 2 
mechanisms through which psychotherapy for BN achieves its effects on reducing depressive 3 
symptoms (Kazdin, 2007). Finally, since 2009, seven additional RCTs of psychotherapy for BN 4 
that have assessed symptoms of depression have been published, allowing for more adequately 5 
powered analyses.  6 
The current meta-analysis therefore aims to examine the efficacy of psychotherapy for 7 
BN on symptoms of depression. In particular, we aim to compare (a) psychotherapy to inactive 8 
control groups; (b) psychotherapy to pharmacotherapy; and (c) CBT to any alternative 9 
psychological treatment on symptoms of depression at post-treatment and follow-up. In addition, 10 
we also aim to test whether these effects are associated with or moderated by the type of 11 
treatment modality, the duration of treatment, the degree of BN symptom improvement, whether 12 
use of antidepressant was an exclusion criterion, and the quality of included studies. 13 
 14 
Method 15 
 This review was conducted in accordance to the latest Preferred Reporting Items for 16 
Systematic Reviews and Meta-analyses (PRISMA) guidelines (Moher, Liberati, Tetzlaff, & 17 
Altman, 2009). 18 
 Search strategy 19 
 The primary search strategy involved searching the Medline and PsycInfo database on the 20 
8th of May 2017. The following terms were searched and combined using the “AND” Boolean 21 
operator: “bulimia nervosa”, bulimi* AND psychotherap*, therap*, treat*, intervention*,“self 22 
help”, self-help, “self care”, self-care, counsel*, bibliotherap*, AND random*, trial*, RCT, 23 
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controlled, allocat*, assign*. The secondary search strategy involved searching the reference list 1 
of included studies and relevant reviews. 2 
Inclusion criteria  3 
 We included (a) published RCTs (b) that compared any form of psychotherapy to either 4 
an inactive control (defined as either a wait-list or placebo control) or pharmacotherapy 5 
condition, or compared CBT to an alternative psychotherapy condition, (c) in individuals with 6 
BN, and (d) reported symptoms of depression at post-treatment or follow-up. Consistent with 7 
previous reviews, psychotherapy was defined as an intervention in which the central element was 8 
verbal communication between a client and a therapist, or as a psychological treatment in the 9 
form of a website or book which the participant worked through somewhat independently but 10 
with guided support from a therapist (e.g., Kolovos, Kleiboer, & Cuijpers, 2016). We therefore 11 
excluded studies that (a) compared two different variants of CBT (e.g., group vs individual), (b) 12 
compared two or more psychotherapies for BN of which one was not cognitive-behavioral based, 13 
and (c) did not or could not provide any data allowing for the calculation of an effect size. We 14 
excluded four studies because an effect size could not be calculated and the relevant data 15 
necessary for calculating an effect size could not be provided (Freeman, Barry, Dunkeld-16 
Turnbull, & Henderson, 1988; Freeman, Sinclair, Turnbull, & Annandale, 1985; Mitchell et al., 17 
2001; Ordman & Kirschenbaum, 1985).  18 
Study selection 19 
 The first author (JL) conducted the search. Once the outputs from the databases were 20 
combined, all duplicate records were removed, and titles and abstracts were screened (by JL). To 21 
maximize identification of relevant articles, all RCTs that compared either a psychological 22 
treatment to a control condition or CBT to an alternative psychotherapy condition in individuals 23 
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with BN were read by the first author in their entirety. This was because measures of depressive 1 
symptoms are typically a secondary outcome reported, and are often not mentioned in the title or 2 
abstract. Authors JL and LB discussed trials in which their inclusion was uncertain. A decision 3 
was made for these trials after consensus was reached. In total, 27 articles (reporting 26 RCTs) 4 
met full inclusion criteria. A flowchart of the search strategy is presented in Figure 1. 5 
Quality assessment  6 
 The validity of trials was assessed using the four criteria of the Cochrane Collaboration 7 
Risk of Bias tool (Higgins & Green, 2011). This risk of bias tool assesses potential sources of 8 
biases in RCTs, such as the adequate generation of allocation sequence, the concealment of 9 
allocation to treatment conditions, blinding of outcome assessors, and dealing with incomplete 10 
data. Dealing with incomplete data was assessed as low risk when ITT analyses were conducted. 11 
The two other criteria of the Cochrane Collaboration tool were not used, as there was no 12 
indication that there were selective outcome reporting or other potential sources of bias. The first 13 
author (JL) and an independent research assistant conducted the assessments. Ratings were 14 
cross-checked, and any discrepancy was discussed and resolved.  15 
.  16 
Meta-analysis  17 
 Meta-analyses were performed for the three main comparisons: (1) psychotherapy versus 18 
inactive controls (2) psychotherapy versus pharmacotherapy; and (3) CBT versus any alternative 19 
psychotherapy approach. When studies compared two different psychotherapy conditions to a 20 
control group, the sample size of the control group was halved to avoid double counting in the 21 
meta-analysis (Higgins & Green, 2011). Where feasible, analyses were also performed at follow-22 
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up (i.e., the last reported follow-up). Intention to treat (ITT) data were analyzed and prioritized 1 
over completer data. 2 
 Effect sizes (standardized mean difference; SMD) were calculated by dividing the 3 
difference between the post-treatment psychotherapy group mean and the post-treatment control 4 
group mean by the pooled standard deviation (Lipsey & Wilson, 2001). If means and standard 5 
deviations were not reported, SMD was calculated using conversion equations from significance 6 
tests (Borenstein, Hedges, Higgins, & Rothstein, 2009). We then converted SMD to Hedges g to 7 
correct for sample size. To compute a pooled effect size, each study’s effect size was weighted 8 
by its inverse variance. Effect sizes were coded such that positive g values indicate that the 9 
psychotherapy (or CBT) condition had lower depressive symptoms than the comparison 10 
condition. Small (0.2), medium (0.5) and large (0.8) effects were specified. Comprehensive 11 
Meta-Analysis was used to calculate effect sizes (Borenstein et al., 2009).  12 
 Since heterogeneity was expected among the studies, a random effects model was used. 13 
Heterogeneity was assessed through the I2 statistic. The I2 statistic assesses the degree of 14 
heterogeneity, where a value of 0% indicates no observed heterogeneity, 25% low heterogeneity, 15 
50% moderate heterogeneity, and 75% as high heterogeneity (Higgins & Thompson, 2002).  16 
 We conducted subgroup analyses to identify potential moderators. For the subgroup 17 
analyses, a pooled effect size was calculated for each subgroup, and a test was conducted to 18 
determine whether the effect sizes for subgroups differ significantly from each other (Borenstein 19 
et al., 2009). A mixed effects model was used, which pools studies within a subgroup using a 20 
random effects model, but tests for differences between subgroups using a fixed effects model 21 
(Borenstein et al., 2009). Significant differences between subgroups are tested by the Qbetween 22 
statistic. Subgroup analyses were conducted for the following categorical moderators: 23 
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psychotherapy modality (therapist-led versus guided self-help); psychotherapy type (CBT versus 1 
other); whether studies excluded participants who were concurrently taking medication (yes 2 
excluded versus not excluded); and study quality (Jadad score ≥ 3 versus Jadad score ≤ 2).  3 
Continuous moderators were tested using meta-regression. We examined whether there 4 
was a relationship between depressive symptoms and (a) the number of treatment sessions 5 
provided, (b) changes in binge eating, and (c) changes in purging. For the meta-regression, the 6 
effect size for changes in depressive symptoms was set as the dependent variable, while the 7 
number of treatment sessions, the effect size for binge eating, and the effect size for purging was 8 
set as the independent variable. Unstandardized coefficients were computed for meta-regression 9 
analyses.  10 
The Fail-Safe N was calculated to address potential publication bias (Rosenthal, 1991). 11 
The Fail-Safe N estimates how many missing studies would need to be included in the meta-12 
analysis for the effect size to become not significantly different from zero. An effect that is 13 
considered robust to publication bias is where the number of studies needed to reduce the effect 14 
size to zero is greater than the number of studies included in the meta-analysis (Rosenthal, 1991). 15 
 16 
Results  17 
Characteristics of included studies 18 
Twenty-six RCTs (27 papers) met full inclusion criteria. Table 1 presents the 19 
characteristics of included studies. All studies sampled adults, with the exception of one study 20 
that sampled adolescents (Le Grange, Lock, Agras, Bryson, & Jo, 2015). The majority of 21 
included studied (k=19) used the Beck Depression Inventory (BDI) as a measure of depressive 22 
symptoms. Ten studies compared psychotherapy for BN to a wait-list control and one compared 23 
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psychotherapy for BN to a pill-placebo. Of these 11 trials, eight delivered a cognitive-behavioral 1 
intervention, with five studies delivering CBT in a therapist-led format, two studies delivering 2 
CBT in a guided self-help format, and one study delivering CBT in a pure self-help format. The 3 
other psychotherapy conditions for this comparison were dialectical behavior therapy (Ncomp=2), 4 
non-specific supportive therapy (Ncomp =2), and behavior therapy (Ncomp =1).  5 
Five studies compared psychotherapy for BN to pharmacotherapy. All pharmacotherapy 6 
trials administered an antidepressant; four administered fluoxetine and one administered 7 
imipramine. Four trials administered CBT as the psychotherapy condition, and one trial 8 
administered CBT and a supportive psychotherapy condition.  9 
Fifteen trials compared CBT to an alternative psychotherapy. Of these, 13 delivered 10 
therapist-led CBT, one delivered guided self-help CBT, and one delivered pure self-help CBT. 11 
Comparison conditions varied, and included behavior therapy, supportive therapy, 12 
psychodynamic therapy, emotion and social mind training, integrative cognitive-affective 13 
therapy, interpersonal psychotherapy, family therapy, and a mindfulness-based intervention (See 14 
Table 1).  15 
Of the 26 RCTs, 14 trials excluded participants who were concurrently taking 16 
medication, whereas 12 trials did not exclude concurrent medication use. Critically, all of these 17 
trials ensured that all participants had been on a stable dose of medication for a minimum of six 18 
weeks, and five of these trials reported how many participants were on medication (<10% of the 19 
total sample were concurrently taking medication).  20 
The quality of included trials varied. Fifteen trials reported an adequate sequence 21 
generation, five trial reported adequate allocation concealment, all trials used a self-report 22 
measure of depressive symptoms, and 13 trials conducted ITT analyses. Four trials met all four 23 
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quality criteria, seven trials met three criteria, six trials met two criteria, and nine trials met just 1 
one criteria. 2 
Psychotherapy vs inactive controls 3 
 Fourteen comparisons of psychotherapy to inactive controls (i.e., wait-list, placebo) on 4 
depressive symptoms were included. The mean effect size for depressive symptoms was 5 
moderate, statistically significant (g= 0.50; 95% CI = 0.22, 0.79), and in favor of the 6 
psychotherapy at post-treatment. There was moderate to high heterogeneity (I2= 71.06). The fail-7 
safe N was 120, indicating no publication bias. When the BDI was used only as the measure of 8 
depressive symptoms (Ncomp= 12), the mean effect size was g= 0.47 (95% CI = 0.15, 0.81). 9 
Analyses were not performed at follow-up as only two studies reported follow-up data.  10 
 The mean effect sizes for binge eating (Ncomp= 7, g= 0.61, 95% CI = 0.21, 1.01) and 11 
purging (Ncomp= 11, g= 0.64, 95% CI =0.32, 0.95) were moderate, statistically significant, and in 12 
favor of psychotherapy interventions. Heterogeneity was large (I2= 70.87, binge eating, I2= 64.16 13 
for purging), and there was no indication of publication bias (fail-safe N = 46 and 110, 14 
respectively).  15 
 Results from the subgroup analyses across the three outcomes at post-treatment can be 16 
seen in Table 2. The effect sizes for depressive symptoms and purging were significantly larger 17 
for studies that delivered therapist-led psychological treatments compared to studies that 18 
delivered self-help treatments. For binge eating, the effect size was significantly larger for 19 
studies that delivered alternative psychological treatments (Ncomp= 2) than for studies that 20 
delivered any mode of CBT (Ncomp= 6). The two studies that contributed to this former subgroup 21 
(alternative interventions) delivered therapist-led DBT. When we performed an analysis in which 22 
the effect size was compared for studies that delivered therapist-led DBT (Ncomp= 2) to studies 23 
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that delivered therapist-led CBT (Ncomp=3), the effect size was still significantly larger (for binge 1 
eating) for DBT studies. The effect size of depressive symptoms for the subgroup of studies that 2 
excluded concurrent medication use was also moderate and statistically significant.  3 
For all studies included in the psychotherapy versus wait-list comparison, meta-4 
regression analyses revealed that there was a positive and statistically significant relationship 5 
between the number of treatment sessions (B= 0.05, 95% CI = 0.01, 0.10, p= .010) and the effect 6 
size for depressive symptoms. There was no statistically significant relationship between the 7 
effect size for depressive symptoms and the effect size for binge eating (B= 0.14, 95% CI = -8 
0.38, 0.67, p= .595) and purging (B= 0.51, 95% CI = -0.03, 1.06, p= .068).  9 
Psychotherapy vs antidepressants  10 
 Only five studies (6 comparisons) were included in this meta-analysis comparing 11 
psychotherapy to antidepressants on depressive symptoms. The mean effect size was small, non-12 
significant, and in favor of antidepressant medication (g= -0.11, 95% CI = -0.34, 0.12). No 13 
heterogeneity was present (I2= 0.68). The mean effect size for binge eating (g= -0.23, 95% CI = -14 
0.61, 0.15) and purging (g= -0.36, 95% CI = -0.77, 0.04) was small and non-significant. Given 15 
the small number of studies included in this analysis, subgroup analyses were not performed. No 16 
follow-up data were available.  17 
Cognitive-behavioral therapy vs alternative psychotherapies 18 
 Eighteen comparisons were included in this meta-analysis comparison of CBT versus 19 
alternative psychotherapies on depressive symptoms. The mean effect size was small, non-20 
significant (g= 0.18, 95% CI = -0.03, 0.38) and in favor of CBT. There was a moderate amount 21 
of heterogeneity present (I2= 54.27). A similar effect size was observed when the BDI was only 22 
used as the measure of depressive symptoms (Ncomp = 13, g= 0.15, 95% CI = -0.09, 0.40). At 23 
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follow-up, the mean effect size was also small, non-significant, and in favor of CBT (Ncomp= 11, 1 
g= 0.14, 95% CI = -0.06, 0.35).  2 
 The mean effect size for binge eating was small to moderate, statistically significant, and 3 
in favor of CBT (Ncomp= 13, g= 0.30, 95% CI = 0.07, 0.53). There was moderate heterogeneity 4 
(I2= 53.56) and no indications of publication bias (Fail-safe N= 33). The mean effect size for 5 
purging was small, non-significant, and in favor of CBT (Ncomp= 17, g= 0.18, 95% CI = -0.05, 6 
0.40). Heterogeneity was moderate (I2= 58.19).  7 
 Results from the subgroup analyses of CBT vs active comparisons across the three 8 
outcomes at post-treatment can be seen in Table 2. CBT was significantly more efficacious than 9 
alternative psychotherapies on reducing symptoms of depression and binge eating only when 10 
CBT was led by a therapist (as opposed to guided self-help CBT). Meta-regression analyses 11 
reveal that there was no relationship between the effect size for depressive symptoms and the 12 
number of treatment sessions administered (B= 0.02, 95% CI= -0.01, 0.06, p=.260). There was a 13 
statistically significant relationship between the effect size for depressive symptoms and the 14 
effect size for binge eating (B= 0.72 95% CI= 0.36, 1.09, p<.001) and purging (B= 0.68, 95% 15 
CI= 0.34, 1.02, p<.001), indicating that greater changes in binge eating and purging during CBT, 16 
relative to alternative psychotherapies, were associated with greater changes in depressive 17 
symptoms (See Figure 2 and 3).  18 
 19 
Discussion 20 
 This meta-analysis examined the efficacy of psychotherapy for BN on symptoms of 21 
depression. Psychotherapy was found to be more effective than inactive controls (i.e., wait-lists) 22 
at post-treatment in reducing depressive and bulimic symptoms in individuals with BN. The 23 
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effect size observed in the current study (g= 0.47) was slightly lower than the effect size 1 
observed in a recent meta-analysis that examined the efficacy of psychotherapy in depressed 2 
populations (g=0.71) (Cuijpers et al., 2013). On the other hand, we found no clear benefit of 3 
psychotherapy over antidepressant medication for individuals with BN in terms of depressive 4 
symptoms. This was not unexpected, as antidepressants have been shown to be just as effective 5 
as psychotherapy in the short-term at reducing depressive symptoms across a range of clinical 6 
conditions (Spielmans, Berman, & Usitalo, 2011). In addition, CBT was equally efficacious to 7 
active psychological controls at reducing depressive and bulimic symptoms at post-treatment. 8 
However, when only therapist-led CBT was analyzed (i.e., self-help studies were omitted), CBT 9 
was significantly more efficacious than active psychological controls at reducing depressive and 10 
bulimic symptoms.  11 
 The type of psychotherapy modality delivered emerged as a consistent moderating 12 
variable. In particular, therapist-led psychological treatments, including CBT, was typically 13 
associated with larger effect sizes in depressive symptom improvement than abbreviated guided 14 
self-help interventions. The size of the effect comparing therapist-led psychological interventions 15 
to wait-list controls (g= 0.47) and therapist-led CBT to active comparisons (g=0.25) was quite 16 
similar to the effect size reported in Hay and colleagues’ meta-analysis (d= 0.69, and d= 0.28, 17 
respectively). The fact that therapist-led psychological treatments are typically longer in duration 18 
than guided self-help treatments suggests that the amount of therapist contact might, at least in 19 
part, play a role in effectively reducing co-occurring symptoms of depression in BN. Indeed, this 20 
dose-response relationship was further supported in our meta-regression analysis which 21 
demonstrated a positive relationship between the number of treatment sessions and the effect size 22 
in depressive symptoms. 23 
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When CBT was compared to active controls, a strong association between the effect size 1 
for depressive symptoms and the effect size for BN symptoms was observed. Specifically, 2 
greater improvements in binge eating and purging were associated with greater improvements in 3 
depressive symptoms during CBT. Although the data precludes causal inferences, these findings 4 
might suggest that improvements in depressive symptoms could be a byproduct of BN symptom 5 
improvement, particularly since a primary goal of CBT is to eliminate BN symptoms via a 6 
collection of treatment strategies designed to directly target the maintaining mechanisms of BN 7 
(Fairburn, Marcus, & Wilson, 1993). CBT for eating disorders has traditionally devoted minimal 8 
attention to  directly targeting depressive symptoms, though enhanced versions of CBT (CBT-E) 9 
now incorporate mood regulation strategies designed to address negative affective states 10 
(Fairburn, 2008). Importantly, only two trials delivered this enhanced version of CBT.   11 
There has been a recent call for prioritizing the delivery of treatments that can target 12 
more than one type of problem, as these “best buy” interventions are purported to be cost-13 
effective and appropriate to implement within the constraints of a local health system (Kazdin, 14 
Fitzsimmons‐Craft, & Wilfley, 2017). Interpersonal psychotherapy has been touted as a best buy 15 
intervention for eating disorders, as IPT can produce improvements in BN symptoms and 16 
interpersonal functioning and general psychiatric symptoms (Wilfley et al., 1993; Wilfley et al., 17 
2002). In relation to the current study, although therapist-led DBT was associated with greater 18 
improvements in binge eating than therapist-led CBT relative to wait-lists, we found therapist-19 
led CBT to directly outperform any other psychotherapy approach on depressive symptom 20 
improvement. Therefore, our findings indicate that therapist-led CBT for BN can be categorized 21 
as a best buy intervention, as CBT can not only reduce BN symptoms and improve quality of life 22 
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(Linardon & Brennan, 2017), but it can also effectively reduce any co-occurring symptoms of 1 
depression. 2 
There are limitations to the current study that must be considered. First, although an 3 
association between improvements in BN and depressive symptoms was observed, the nature of 4 
the analyses did not allow us to determine whether improvements in depressive symptoms were a 5 
cause or a consequence of the improvements observed in bulimic symptoms. While there is 6 
reason to suspect that improvements in depressive symptoms are a consequence of BN symptom 7 
improvement (Puccio et al., 2016), particularly since a rapid reduction in BN symptoms 8 
independent of depressive symptoms are often observed within the first few weeks of CBT 9 
(Linardon, Brennan, & de la Piedad Garcia, 2016; Linardon, de la Piedad Garcia, & Brennan, 10 
2016; Thompson-Brenner, Shingleton, Sauer-Zavala, Richards, & Pratt, 2015; Vall & Wade, 11 
2015), the possibility of reverse causality cannot be ruled out until further research examines the 12 
temporal nature of these relationships, as has been conducted with changes in therapeutic 13 
alliance (Graves et al., 2017). Second, the number of comparisons contributing to some of the 14 
subgroup analyses was small. Thus, we may have lacked adequate statistical power to detect 15 
some moderation effects (Borenstein et al., 2009). Third, the current findings only apply to 16 
outcomes at post-treatment assessment. Too few studies assessed the efficacy of psychotherapy 17 
for BN on depressive symptoms at follow-up. Thus, it is unclear whether the beneficial effects of 18 
psychotherapy for BN on depressive symptoms are sustained well after treatment ends. Follow-19 
up assessments are therefore important. Finally, only English studies that were published in peer-20 
review journals were included. Publication bias was not evident in the current meta-analysis. 21 
However, because unpublished studies are more likely to report non-significant findings, our 22 
effect sizes might have been inflated.  23 
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 In sum, the current study demonstrated that psychotherapy for BN is efficacious for not 1 
only reducing symptoms of BN, but also for reducing symptoms of depression. The greatest 2 
improvements in depressive symptoms are made when psychotherapy is led by a therapist rather 3 
than when delivered in a guided self-help format. The current findings also indicate that greater 4 
improvements in depressive symptoms during CBT might be explained by greater improvements 5 
in BN symptoms. The fact that therapist-led CBT for BN was more effective at reducing 6 
depressive symptoms than alternative psychotherapies suggests that CBT for BN has a powerful 7 
therapeutic effect for more than one type of problem, and can therefore be categorized as a “best 8 
buy” psychological treatment for BN.  9 
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Table 1 
Characteristics of included studies  
Study Sample 
age (M 
SD) 
CBT intervention (n) Alternative 
psychotherapy (n) 
Inactive control or 
pharmacotherapy  
condition (n) 
Depression 
measure 
Concurrent 
medication use an 
exclusion criteria? 
Quality 
assessment  
(Agras, Schneider, 
Arnow, Raeburn, & 
Telch, 1989) 
29.2 (8.6) Therapist-led (n=17) 
14 individual sessions 
Self-monitoring group 
(n=16)  
14 individual sessions 
 
Wait-list (n=18) BDI  Yes + ? SR - 
(Banasiak, Paxton, & 
Hay, 2005) 
29.5 (8.72) GSH (n=54) 
9 Sessions  
 
- Wait-list (n=55) BDI Yes + + SR + 
(Carter et al., 2003) 27.0 (8.00) PSH (n=28) 
8 sessions  
Supportive PSH (n=28) 
8 sessions 
 
Wait-list (n=29) BDI No. n= not 
specified   
+ + SR + 
(Cooper & Steere, 
1995) 
23.8 (NA) Therapist-led (n=13) 
19 sessions  
Behavior therapy (n=13) 
19 sessions 
 
- BDI No. n = not 
specified   
? ? SR - 
(Davis, McVey, 
Heinmaa, Rockert, & 
Kennedy, 1999) 
 
27.1 (5.3) Therapist-led (n=37) 
20 sessions  
- Wait-list (n=19) BDI Yes ? ? SR - 
(Fairburn et al., 1991) 24.2 (NA) Therapist-led (n=21) 
19 sessions  
IPT (n=22) 
 
 
BT (n=19) 
- BDI No. n = not 
specified   
? ? SR - 
 
(Fairburn et al., 1986) 22.9 (4.4) Therapist-led (n=11) 
19 sessions  
Short-term focal 
psychotherapy (n=11) 
 
- MADRS Yes + ? SR - 
(Garner et al., 1993) 23.7 (4.4) Therapist-led (n=25) 
19 sessions  
Supportive expressive 
therapy (n=25) 
19 sessions  
- BDI No. n = not 
specified   
+ - SR - 
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(Goldbloom et al., 
1997) 
25.8 (5.5) Therapist-led (n=14) 
16 sessions  
 
- Fluoxetine (n=12) BDI Yes (for CBT 
group) 
? ? SR - 
(Gulec et al., 2014) 28.2 (7.8) Online non-specific 
internet based 
intervention (n=44) 
6 sessions  
 
- Wait-list (n-51) DASS  No. n = not 
specified   
? ? SR - 
(Hill, Craighead, & 
Safer, 2011) 
22.6 (5.6) - DBT-AF (n=18) 
12 sessions 
 
Wait-list (n=14) BDI No. n = 2 
participants on 
medication   
  
+ ? SR +  
(Hsu et al., 2001) 24.5 (6.4) Therapist-led (n= 24) 
12 sessions 
Support group (n= 24) 
12 sessions  
 
- HADRS Yes + ? SR + 
(Jacobi, Dahme, & 
Dittmann, 2002) 
 
26.0 (5.8) Therapist-led (n=19) 
20 sessions  
- Fluoxetine (n=16) BDI Yes (for CBT 
group) 
? ? SR + 
(Lavender et al., 2012) 27.7 (7.6) Therapist-led (n=21) 
17 sessions  
Emotion social mind 
training (n=23) 
 
- DASS No. n = not 
specified   
+ ? SR + 
(Le Grange et al., 
2015) 
 
15.7 (1.5) Therapist-led (n=58) 
18 sessions  
FBT-BN (n=51) - BDI No. n = 10 
participants   
+ + SR + 
(Lee & Rush, 1986) 
 
27.7 (5.3) Therapist-led (n=15) 
12 sessions  
- Wait-list (n=15) BDI Yes. + ? SR + 
(Leitenberg, Rosen, 
Gross, Nudelman, & 
Vara, 1988) 
 
25.0 (5.4) Therapist-led (n=22) 
24 sessions  
Exposure response 
prevention (n=11) 
24 sessions 
 
Exposure response 
prevention 2 (n=12) 
24 sessions 
- BDI Yes. ? ? SR - 
  25 
 
(Mitchell et al., 1990) 22.8 (4.3) Therapist-led (n=33) 
10 sessions 
 
- Imipramine (n=45) HADRS Yes (for CBT 
group) 
? - SR - 
(Poulsen et al., 2014) 25.8 (4.9) Therapist-led (n=36) 
20 sessions  
Psychoanalysis (n=36) 
 
- BDI No. n = 10 
participants   
+ + SR + 
(Safer et al., 2001) 34.0 (11.0)  - Therapist-led DBT 
(n=14) 
20 sessions 
 
Wait-list (n=15) BDI Yes. ? ? SR - 
(Sánchez-Ortiz et al., 
2011) 
 
23.9 (5.9) GSH (n=31) 
Sessions = NS 
- Wait-list (n=36) HADS  No. n = 6 
participants   
+ + SR - 
(Steele & Wade, 2008) 25.7 (5.6) GSH (n=15); 
8 sessions  
CBT GSH for 
perfectionism  (n= 17) 
8 sessions 
 
Mindfulness-based CT 
(n=15) 
- DASS No. n = 10 
participants   
+ - SR + 
(Thackwray, Smith, 
Bodfish, & Meyers, 
1993) 
31.3 (10.4) Therapist-led (n=13) 
8 sessions  
BT (n=13) 
 
Non-specific self-
monitoring treatment 
(n=13) 
 
- BDI Yes. ? ? SR - 
(Walsh, Fairburn, 
Mickley, Sysko, & 
Parides, 2004) 
30.6 (7.8) GSH (n=25) 
8 sessions  
- Fluoxetine (n=20) 
Pill-placebo (n=22) 
BDI Yes. ? ? SR + 
(Walsh et al., 1997) 25.8 (4.4) Therapist-led (n=25) 
20 sessions  
Supportive expressive 
therapy (n=22) 
20 sessions 
 
Fluoxetine (n=28) BDI Yes. ? ? SR + 
(Wonderlich et al., 
2014) 
27.3 (9.6) Therapist-led (n=36) 
21 sessions  
Integrative cognitive 
affective therapy (n=36) 
- BDI No. n = not 
specified    
+ ? SR + 
Note: GSH= guided self-help; DBT-AF= dialectical behavior therapy – appetite focused; CT= cognitive therapy; FBT = family-based therapy; BDI= beck depression 
inventory; HADS = hospital depression and anxiety scale; DASS= Depression, anxiety and stress scale; MADRS= Montgomery Asberg depression rating scale; In the 
  26 
 
quality assessment column a + sign (low risk), a “?” (unclear), or a - sign (high risk)  is given for the four items of risk of bias: allocation sequence; concealment of 
allocation to conditions; blinding of assessors; and intention-to treat analyses. For Blinding of assessor we reported “SR” when only self-report outcome measures were 
used 
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Table 2 
Subgroup analyses for the psychotherapy vs inactive comparison and the CBT vs active comparisons   
Comparison   Depressive symptoms  Binge eating  Purging  
 Subgroups Ncomp g (95% CI) Qbp Ncomp g (95% CI) Qbp Ncomp g (95% CI) Qbp 
Psychotherapy vs. 
inactive control 
          
 Psychotherapy          
   CBT   8 0.52 (0.12, 0.92)  5 0.37 (0.02, 0.71)  7 0.45 (0.11, 0.81)  
   Other psychotherapy 6 0.48 (0.03, 0.95)  2 1.41 (0.67, 2.15)  4 1.00 (0.43, 1.56)  
    .907   .008   .090 
   TL CBT only  5 0.92 (0.45, 1.37)  3 0.49 (0.12, 0.86)  5 0.64 (0.37, 0.92)  
   TL other psychotherapy  4 0.70 (0.16, 1.24)  2 1.41 (0.67, 2.15)  4 1.00 (0.43, 1.56)  
    .548   .012   .144 
 Modality           
   Therapist-led 8 0.78 (0.42, 1.15)  4 0.94 (0.41, 1.48)  8 0.89 (0.58, 1.20)  
   Guided self-help  
  Pure self-help  
4 
2 
0.41 (-0.01, 0.83) 
-0.25 (-0.85, 0.36) 
 3 0.26 (-0.27, 0.79)  3 0.14 (-0.25, 0.53)  
    .016   .075   .003 
 Concurrent med use           
    Excluded  9 0.61 (0.23, 0.99)  5 0.61 (0.77, 1.14)  9 0.67 (0.29, 1.04)  
    Not Excluded 5 0.33 (-0.14, 0.81)  2 0.64 (-0.19, 1.48)  2 0.51 (-0.24, 1.27)  
    .372   .955   .795 
CBT vs. active control           
 Modality            
   Therapist-led 15 0.25 (0.03, 0.46)  15 0.33 (0.08, 0.58)  15 0.20 (-0.04, 0.44)  
   Guided self-help  
  Pure self-help  
2 
1 
0.05 (-0.57, 0.68) 
-0.52 (-1.30, 0.26) 
 3 0.07 (-0.58, 0.72)  2 -0.02 (-0.06, 1.03)  
    .171   .455   .542 
 Concurrent med use           
    Excluded  7 0.39 (0.04, 0.73)  10 0.25 (-0.01, 0.51)  7 0.23 (-0.14, 0.61)  
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    Not excluded 11 0.07 (-0.17, 0.31)  3 0.47 (-0.03, 0.97)  10 0.14 (-0.14, 0.43)  
    .134   .458   .820 
Note: Ncomp= number of comparisons; Qbp = p value test of whether the effect size for subgroups are significant; CBT= cognitive-behavioral therapy; TL= therapist-led; 
med= medication; bolded numbers signify statistical significance.  
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Figure 2:  
Meta-regression of the relationship between binge eating and depressive symptom severity for the CBT vs active comparison 
Note: Studies are represented by circles. The size of the circle is proportional to each study’s weight; larger circles are studies that have a smaller standard error 
and a smaller variance component.   
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Figure 3:  
Meta-regression of the relationship between purging and depressive symptom severity for the CBT vs active comparison 
Note: Studies are represented by circles. The size of the circle is proportional to each study’s weight; larger circles are studies that have a smaller standard error 
and a smaller variance component.   
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